The AFP/AFU combination was also notable for early-stage HBV-HCC and HCV-HCC [AUC: 0.776 (0.712–0.831), sensitivity: 52.5%, specificity: 91.6%] in the test cohort (Figure 5G). The gene discussed is AFP; the disease is hepatocellular carcinoma.